Published in
Oxford University Press, Japanese Journal of Clinical Oncology, 9(49), p. 856-861, 2019
DOI: 10.1093/jjco/hyz074
Links
Tools
Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study
Journal article published in 2019 by
Kei Ito,
Satoshi Kito,
Yujiro Nakajima 
,
Takuya Shimizuguchi,
Hiroaki Ogawa,
Keiji Nihei,
Hiroshi Tanaka,
Nao Kino,
Toshiharu Yasugi,
Katsuyuki Karasawa
,
Takuya Shimizuguchi,
Hiroaki Ogawa,
Keiji Nihei,
Hiroshi Tanaka,
Nao Kino,
Toshiharu Yasugi,
Katsuyuki Karasawa
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
A phase I clinical trial was conducted to determine the recommended dose of SBRT boost for cervical cancer. The recommended dose was 22.5 Gy in three fractions.